Erratum to 'Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: A case study using ultra deep pyrosequencing' [Journal of Clinical Virology 66 (2015) 38-43], DOI: 10.1016/j.jcv.2015.02.001;Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: A case study using ultra deep pyrosequencing

Journal of Clinical Virology

Volumn 66, Issue , 2015, Pages 38-43

  Bartolini, Barbara ^a   Lionetti, Raffaella ^a   Giombini, Emanuela ^a   Sias, Catia ^a   Taibi, Chiara ^a   Montalbano, Marzia ^a   Gianpiero, D'Offizi ^a   McPhee, Fiona ^b   Hughes, Eric A ^b   Zhou, Nannan ^b   Ippolito, Giuseppe ^a   Garbuglia, Anna Rosa ^a   Capobianchi, Maria R ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Daclatasvir; Genotype 4; Hepatitis c virus; NS5A; UDPS

Indexed keywords

AMINO ACID; DACLATASVIR; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; INTERFERON; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; GENETIC HETEROGENEITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; PYROSEQUENCING; RESISTANCE ASSOCIATED VARIANT; SCREENING; VIRUS LOAD; ADOLESCENT; ANTIVIRAL RESISTANCE; CLASSIFICATION; DRUG EFFECTS; GENETIC VARIABILITY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; TREATMENT FAILURE; VIROLOGY;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTERFERONS; MIDDLE AGED; RIBAVIRIN; TREATMENT FAILURE; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84926622123     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.05.014     Document Type: Erratum

References (27)

1. Messina J.P., Humphreys I., Flaxman A., Brown A., Cooke G.S., Pybus O.G., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatol. Hepatol. 2015, Jan 61(January (1)):77-87. Epub 2014 July 28. 10.1002/hep.27259.
2. Guerra J., Garenne M., Mohamed M.K., Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J. Viral Hepatitis 2012, 19:560-567.
3. Talaat M., El-Sayed N., Kandeel A., Azab M.A., Afifi S., Youssef F.G., et al. Sentinel surveillance for patients with acute hepatitis in Egypt, 2001-04. East Mediterr. Health J. 2010, 16:134-140.
4. El Gaafary M.M., Rekacewicz C., Abdel-Rahman A.G., Allam M.F., El Hosseiny M., Hamid M.A., et al. Surveillance of acute hepatitis C in Cairo, Egypt. J. Med. Virol 2005, 76:520-525.
5. Kamal S.M. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011, 31(Suppl. 1):45-52. 10.1111/j.1478-3231.2010.02385.x.
6. Garbuglia A.R., Lapa D., Sias C., Testa A., Capobianchi M.R. Molecular and epidemiological profiles of Hepatitis C virus genotype 4 in Regione Lazio, Italy. Virologie European Congress of Virology 2013, Poster 365.
7. Benhamou Y., Moussalli J., Ratziu V., Lebray P., De Backer K., De Meyer S., et al. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J. Infect. Dis. 2013, 208:1000-1007. 10.1093/infdis/jit274.
8. Suk-Fong Lok A. HCV NS5A inhibitors in development. Clin. Liver Dis. 2013, 17:111-121. 10.1016/j.cld.2012.09.006.
9. Wang C., Jia L., Huang H., Qiu D., Valera L., Huang X., Sun J.H., et al. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob. Agents Chemother. 2012, 56:1588-1590.
10. Wang C., Jia L., O'Boyle D.R., Sun J.H., Rigat K., Valera L., et al. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob. Agents Chemother. 2014, 58:5155-5163.
11. Fridell R.A., Wang C., Sun J.H., O'Boyle D.R., Nower P., Valera L., et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011, 54:1924-1935.
12. Lok A.S., Gardiner D.F., Lawitz E., Martorell C., Everson G.T., Ghalib R., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012, 366:216-222.
13. McPhee F., Hernandez D., Yu F., Ueland J., Monikowski A., Carifa A., et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013, 58:902-911. 10.1002/hep.26388.
14. Karino Y., Toyota J., Ikeda K., Suzuki F., Chayama K., Kawakami Y., et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J. Hepatol. 2013, 58:646-654. 10.1016/j.jhep.2012.11.012.
15. McPhee F., Hernandez D., Zhou N., Yu F., Ueland J., Monikowski A., et al. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir. Ther. 2014, 2:2. 10.3851/IMP2729.
16. McPhee F., Zhou N., Ueland J., Yu F., Yang X., Monikowski A., et al. Pre-existence, emergence and persistence of HCV genotype 4 NS5A resitance variants from the phase 2B COMMAND-1 study: daclatasvir plus peginterferon-alfa/ribavirin in treatment-naïve patients. J. Hepatol. 2013, 58(Suppl):S492.
17. Hézode C., Hirschfield G.M., Ghesquiere W., Sievert W., Rodriguez-Torres M., Shafran S.D., et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2014, 0:1-9. 10.1136/gutjnl-2014-307498.
18. Visco-Comandini U., Lapa D., Taibi C., Angeletti C., Capobianchi M.R., Garbuglia A.R. No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance. Dig. Liver Dis. 2014, 46:348-352. 10.1016/j.dld.2013.11.006.
19. Simen B.B., Simons J.F., Hullsiek K.H., Novak R.M., Macarthur R.D., Baxter J.D., Huang C., et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 2009, 199(March 1 (5)):693-701. 10.1086/596736.
20. Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014, 59:318-327. 10.1002/hep.26744.
21. Fridell R.A., Qiu D., Wang C., Valera L., Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 2010, 54:3641-3650.
22. Schnell G., Tripathi R., Beyer J., Reisch T., Krishnan P., Baykal T., et al. Identification and treatment of multiple subtypes of HCV genotype 4 in the PEARL-I study with ombitasvir and ABT-450/r ±ribavirin. Proceeding of the American association for the Study of Liver Diseases AASLD 2015.
23. Bartolini B., Lionetti R., Giombini E., Taibi C., Montalbano M., D'Offizi G., et al. NS5A variability and dynamics of resistance-associated mutations in HCV genotype 4 patients, naive to treatment receiving triple therapy with DACLATASVIR+PEG-IFN/RBV, assessed by ultra deep sequencing. Proceeding of the American association for the Study of Liver Diseases AASLD 2015.
24. Bilello J.P., Lallos L.B., McCarville J.F., La Colla M., Serra I., Chapron C., et al. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 2014, 58(August (8)):4431-4442. 10.1128/AAC.2,777-13.
25. Galmozzi E., Aghemo A., Colombo M. Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders. Hepatology 2013, 57:2087. 10.1002/hep.25924.
26. Murakami E., Imamura M., Hayes C.N., Abe H., Hiraga N., Honda Y., et al. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. Antimicrob. Agents Chemother. 2014, 58:2105-2112. 10.1128/AAC.2068-13.
27. Miura M., Maekawa S., Sato M., Komatsu N., Tatsumi A., Takano S., Amemiya F., et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol. Res. 2014, 2:5. 10.1111/hepr.12316.